Niagen Bioscience (NAGE) Equity Average (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Equity Average data on file, last reported at $79.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $79.4 million, up 56.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.4 million (up 56.61% YoY), and the FY2025 annual result was $61.3 million, up 64.49% from the prior year.
• Equity Average grew to $79.4 million in Q1 2026 per NAGE's latest filing, from $73.6 million in the prior quarter.
• Over five years, Equity Average peaked at $79.4 million in Q1 2026 and troughed at $20.9 million in Q3 2022.
• A 5-year average of $39.5 million and a median of $28.8 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average plunged 46.13% in 2022, then surged 107.22% in 2025.
• A 5-year view of Equity Average shows it stood at $24.8 million in 2022, then rose by 12.21% to $27.9 million in 2023, then soared by 44.29% to $40.2 million in 2024, then soared by 82.95% to $73.6 million in 2025, then climbed by 7.92% to $79.4 million in 2026.
• Business Quant data shows NAGE's Equity Average at $79.4 million in Q1 2026, $73.6 million in Q4 2025, and $67.4 million in Q3 2025.